ArticleInvestigational new drugs2022

FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells.

Chie Ishikawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.